Related Experiment Videos

Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies

Y Nakanuma1, K Harada, K Kaji

  • 1Department of Pathology (II), Kanazawa University School of Medicine, Japan.

Liver
|February 10, 1998
PubMed

Insights

Most patients with primary biliary cirrhosis (PBC) negative for antimitochondrial antibodies (AMA) still show PBC features and react to specific mitochondrial proteins. This suggests a broader antibody profile in AMA-negative PBC patients.

Area of Science:

  • Immunology
  • Hepatology
  • Autoimmunity

Background:

  • Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterized by antimitochondrial antibodies (AMA) and bile duct destruction.
  • A subset of PBC patients (~5%) present with PBC features but lack AMA detectable by indirect immunofluorescence (IF).
  • The clinical and immunological significance of AMA-negative PBC remains incompletely understood.

Purpose of the Study:

  • To investigate the clinicopathological features of AMA-negative PBC patients.
  • To examine antibody reactivity against recombinant (r)-mitochondrial polypeptides in AMA-negative PBC patients.
  • To compare AMA-negative and AMA-positive PBC patient groups.

Main Methods:

  • Clinicopathological data were collected from 30 AMA-negative and 38 AMA-positive PBC patients.
  • AMA presence was confirmed by indirect immunofluorescence (IF).
  • Antibody reactivity against specific recombinant mitochondrial polypeptides (E1 alpha of pyruvate dehydrogenase complex, E2 subunit of pyruvate dehydrogenase complex, branched-chain 2-oxo-acid dehydrogenase complex) was assessed by immunoblotting.

Main Results:

  • AMA-negative and AMA-positive PBC groups showed minimal differences in clinical, serological, and histopathological features.
  • Among 30 IF-tested AMA-negative PBC patients, 24 reacted to at least one recombinant mitochondrial polypeptide, primarily those of the 2-oxo-acid dehydrogenase complex.
  • Six AMA-negative patients were asymptomatic with early-stage histological findings, one of whom had anti-smooth muscle antibody.

Conclusions:

  • The majority of AMA-negative PBC patients exhibit clinicopathological and serological similarities to AMA-positive PBC patients.
  • Most AMA-negative PBC patients demonstrate reactivity to specific recombinant mitochondrial polypeptides, particularly those of the 2-oxo-acid dehydrogenase complex.
  • These findings suggest that AMA-negative PBC patients possess a broad spectrum of autoantibody profiles, aligning with the overall characteristics of PBC.

Related Concept Videos